Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Receivables (2016 - 2025)

Marimed (MRMD) has disclosed Receivables for 14 consecutive years, with $8.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 4.36% to $8.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.0 million, a 4.36% increase, with the full-year FY2024 number at $8.7 million, up 19.69% from a year prior.
  • Receivables was $8.0 million for Q3 2025 at Marimed, up from $7.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $9.2 million in Q1 2025 to a low of $4.4 million in Q1 2023.
  • A 5-year average of $7.3 million and a median of $7.6 million in 2024 define the central range for Receivables.
  • Biggest YoY gain for Receivables was 181.12% in 2021; the steepest drop was 81.31% in 2021.
  • Marimed's Receivables stood at $6.7 million in 2021, then surged by 31.85% to $8.8 million in 2022, then dropped by 16.9% to $7.3 million in 2023, then rose by 19.69% to $8.7 million in 2024, then dropped by 9.0% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Receivables are $8.0 million (Q3 2025), $7.7 million (Q2 2025), and $9.2 million (Q1 2025).